Dapagliflozin / metformin sustained release tablet, preparation method therefor, and application thereof
By designing the metformin sustained-release core, isolation layer and dagliflozin drug-on-solution layer in dagliflozin metformin sustained-release tablets, and adding a film coating layer, the content uniformity and high production cost in the prior art are solved. The problem of this paper has achieved efficient drug dissolution and simplified production process.
Patent Information
- Application Number
- PCT/CN2023/126083
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2023-10-24
- Publication Date
- 2024-11-21
AI Technical Summary
The dosages of metformin and dapagliflozin in the existing sustained-release preparations of metformin and dapagliflozin are very different, resulting in the content uniformity of the content when prepared into a double-layer tablet, and the production cost is high and the efficiency is low, making it prone to delayed drug adsorption and dissolution. question.
Adopting an internal to external structural design, including metformin sustained-release tablet core, isolation layer and dapagliflozin drug supernatant layer, and a film coating layer, the drug is improved through the group distribution ratio control of the isolation layer and drug supernatant layer. The uniformity of content and simplify the production process through the coating process and reduce costs.
The high content uniformity of dapagliflozin metformin sustained release tablets and good drug dissolution effect are achieved, which reduces production costs, avoids the problem of drug adsorption and dissolution lag, and improves production efficiency.
Smart Images

Figure CN2023126083_21112024_PF_FP_ABST
Abstract
Description
A dapagliflozin metformin sustained-release tablet and its preparation method and application
[0001] This application claims priority to the Chinese patent application filed with the Patent Office of China on May 15, 2023, with application number CN202310547897.9 and invention name “A dapagliflozin metformin sustained-release tablet, its preparation method and application”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present invention relates to the technical field of pharmaceutical materials, and in particular to a dapagliflozin metformin sustained-release tablet, a preparation method thereof, and an application thereof. Background Art
[0003] Diabetes is a group of metabolic diseases characterized by high blood sugar levels. Based on its pathogenesis, diabetes can be divided into type 1 diabetes, type 2 diabetes, gestational diabetes, and special types of diabetes. Type 2 diabetes is the most common type clinically, accounting for over 90% of the diabetic population. In 2020, the top category in the domestic diabetes medication market was insulin and its analogs, accounting for 45.1%. This was followed by traditional oral diabetes medications such as biguanides and α-glucosidase inhibitors, which accounted for 13.2% and 12.1%, respectively. The combined share of these three categories exceeded 70%.
[0004] Currently, combination therapy is an important treatment option, and compound hypoglycemic drugs are poised for rapid growth. Diabetes treatment guidelines from various countries suggest that dual or even triple therapy with metformin, combined with various antidiabetic drugs, can rapidly lower blood sugar levels while also preventing and treating various complications of diabetes. This has become a crucial approach to diabetes treatment. In recent years, international pharmaceutical companies have launched a variety of compound hypoglycemic drugs, leveraging complementary mechanisms to enhance efficacy and extend product lifecycles. Compound hypoglycemic drugs are expected to maintain rapid growth in the future.
[0005] Dapagliflozin / metformin extended-release tablets are a combination preparation indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Dapagliflozin / extended-release metformin hydrochloride has been approved by the FDA in multiple dosage strengths, including 2.5mg / 1000mg, 5mg / 500mg, 5mg / 1000mg, 10mg / 500mg, and 10mg / 1000mg, under the trade name XIGDUO XR. Currently, this drug has not entered the Chinese market, and no domestically produced dapagliflozin / metformin extended-release tablets are on the market.
[0006] Chinese patent CN115414347A discloses a dapagliflozin / metformin sustained-release formulation comprising a first layer containing metformin, a second layer containing dapagliflozin, and a film coating layer covering the first and second layers. The patent describes metformin and dapagliflozin in a bilayer tablet format. Due to the significant disparity in metformin and dapagliflozin dosages, preparing a bilayer tablet with both can result in substandard content uniformity.
[0007] Summary of the Invention
[0008] In view of this, the present invention provides a dapagliflozin metformin sustained-release tablet and its preparation method and application. The dapagliflozin metformin sustained-release tablet provided by the present invention has good content uniformity, low cost, and good dissolution effect of the drug component.
[0009] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0010] A dapagliflozin metformin sustained-release tablet, characterized in that it comprises, from the inside to the outside, a metformin sustained-release tablet core, an isolation layer, a dapagliflozin drug layer, and a film coating layer;
[0011] The components of the metformin sustained-release tablet core include metformin hydrochloride, a binder, a hydrophilic gel skeleton sustained-release material, a glidant and a lubricant;
[0012] The components of the isolation layer include hydroxypropyl cellulose, a plasticizer and an anti-sticking agent;
[0013] The components of the dapagliflozin upper drug layer include dapagliflozin, a diluent, a plasticizer, a disintegrant and an anti-adhesive agent.
[0014] Preferably, based on the total mass percentage of the dapagliflozin metformin sustained-release tablet as 100%, the mass percentage of each component in the metformin sustained-release tablet core is: metformin hydrochloride 40-79%, binder 2-7%, hydrophilic gel skeleton sustained-release material 10-40%, glidant 0.1-2%, lubricant 1-10%;
[0015] Taking the total mass percentage of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentages of the components in the isolation layer are: 0.5-3% hydroxypropyl cellulose, 1.5-4% plasticizer, and 0.05-1.2% anti-adhesive agent;
[0016] Taking the total mass percentage of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentage of each component in the dapagliflozin upper drug layer is: dapagliflozin 0.2-2%, diluent 2-15%, plasticizer 0.5-4%, disintegrant 1.5-5%, and anti-adhesive agent 0.05-3%.
[0017] Preferably, the film coating layer comprises Opadry coating powder, and based on the total mass percentage of the dapagliflozin metformin sustained-release tablets being 100%, the mass percentage of the Opadry coating powder is 1-4%.
[0018] Preferably, the binder is one or more of povidone, starch slurry, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol and sucrose;
[0019] The hydrophilic gel skeleton sustained-release material is one or more of hypromellose, sodium carboxymethylcellulose, methylcellulose, povidone, carbomer, alginate and chitosan;
[0020] The lubricant is one or more of magnesium stearate, sodium stearyl fumarate and talc;
[0021] The glidant is colloidal silicon dioxide and / or talc.
[0022] Preferably, the plasticizers used in the isolation layer and the dapagliflozin upper drug layer are independently selected from one or more of polyethylene glycol, microcrystalline cellulose, polyvinyl pyrrolidone and a water-soluble surfactant;
[0023] The anti-adhesive agents used in the isolation layer and the dapagliflozin upper drug layer are independently one or more of talc, magnesium stearate, silicon dioxide and lauryl sulfate;
[0024] The diluent is one or more of lactose, mannitol, sorbitol, dextrin, starch, microcrystalline cellulose, inorganic calcium salt and powdered sugar;
[0025] The disintegrant is one or more of hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl starch and dry starch.
[0026] Preferably, the components of the metformin sustained-release tablet core include metformin hydrochloride, povidone, hypromellose, colloidal silicon dioxide and sodium stearyl fumarate, or include metformin hydrochloride, sodium carboxymethyl cellulose, hypromellose, colloidal silicon dioxide and sodium stearyl fumarate;
[0027] The components of the isolation layer include hydroxypropyl cellulose, polyethylene glycol and talc;
[0028] The ingredients of the dapagliflozin upper drug layer include dapagliflozin, polyethylene glycol, talc, lactose and hydroxypropyl cellulose, or include dapagliflozin, polyethylene glycol, talc, mannitol and hydroxypropyl cellulose.
[0029] Preferably, the content of metformin hydrochloride in each dapagliflozin metformin sustained-release tablet is 400-1200 mg, and the content of dapagliflozin is 1-12 mg; the weight of each dapagliflozin metformin sustained-release tablet is 850-1800 mg.
[0030] The present invention also provides a method for preparing the dapagliflozin metformin sustained-release tablets described in the above scheme, comprising the following steps:
[0031] Wetting metformin hydrochloride and a binder and then performing wet granulation, mixing the obtained drug granules with a hydrophilic gel matrix sustained-release material, a lubricant, and a glidant, and tableting to obtain metformin sustained-release tablet cores;
[0032] mixing the components of the isolation layer with water to obtain an isolation layer coating paste; and coating the metformin sustained-release tablet core with the isolation layer coating paste to obtain metformin sustained-release isolation-coated tablets;
[0033] Mixing the components of the dapagliflozin upper drug layer with water to obtain an upper drug solution; applying the upper drug solution to the metformin sustained-release isolation-coated tablets to obtain dapagliflozin metformin sustained-release tablets;
[0034] The dapagliflozin metformin sustained-release tablets are film-coated with a film coating slurry to obtain the dapagliflozin metformin sustained-release tablets.
[0035] Preferably, the isolation layer coating, drug application and film layer coating are all carried out in a coating pan; the operating parameters of the isolation layer coating include: the spray rate of the isolation layer coating slurry is 50-100 g / min, the rotation speed of the coating pan is 3-8 r / min, and the temperature of the material in the coating pan is 38-45°C;
[0036] The operating parameters of the drug application include: a spray rate of the drug solution of 50 to 230 g / min, a rotation speed of the coating pan of 3 to 12 r / min, and a temperature of the material in the coating pan of 38 to 45°C;
[0037] The operating parameters of the film layer coating include: the spraying rate of the film layer coating slurry is 50-100 g / min, the rotation speed of the coating pan is 3-8 r / min, and the temperature of the material in the coating pan is 38-45°C.
[0038] The present invention also provides the use of the dapagliflozin metformin sustained-release tablets described in the above scheme or the dapagliflozin metformin sustained-release tablets prepared by the preparation method described in the above scheme in the preparation of drugs for treating type 2 diabetes.
[0039] The present invention provides a dapagliflozin metformin sustained-release tablet, which comprises, from the inside to the outside, a metformin sustained-release tablet core, an isolation layer, a dapagliflozin upper drug layer and a film coating layer; the components of the metformin sustained-release tablet core include metformin hydrochloride, a binder, a hydrophilic gel skeleton sustained-release material, a glidant and a lubricant; the components of the isolation layer include hydroxypropyl cellulose, a plasticizer and an anti-adhesive agent; the components of the dapagliflozin upper drug layer include dapagliflozin, a diluent, a plasticizer, a disintegrant and an anti-adhesive agent. The present invention adopts a coating method to coat dapagliflozin on the outside of the metformin tablet core. The content of dapagliflozin can be easily controlled by weight gain, which is beneficial to improving the uniformity of the drug content. At the same time, the present invention provides an isolation layer between the metformin sustained-release tablet core and the dapagliflozin drug layer, which can increase the uniformity of the drug content. The results of the examples show that the uniformity of the dapagliflozin metformin sustained-release tablets prepared by the present invention is A+2.2S≤8.2. In addition, the dapagliflozin material has a small particle size and is easy to adsorb. If the drug is directly applied on the surface of the metformin sustained-release tablet core, the problem of delayed adsorption and dissolution of the dapagliflozin raw material is likely to occur. The present invention can avoid the above problems by providing an isolation layer, thereby ensuring the effective dissolution of dapagliflozin.
[0040] Furthermore, the present invention controls the components and ratios of the dapagliflozin drug layer, which can further improve the uniformity of the drug coating.
[0041] The present invention also provides a method for preparing the dapagliflozin metformin sustained-release tablets described in the above scheme. In the conventional method, metformin and dapagliflozin are prepared into double-layer tablets, which requires the use of a double-layer tablet press. The process is complex and the cost is high. In addition, material loss is likely to occur during the tableting process, which increases the preparation cost. The present invention adopts a coating method to sequentially coat the isolation layer, the upper drug layer and the film coating layer on the surface of the metformin sustained-release tablet core. The operation method is simple and does not require the use of a double-layer tablet press, thereby solving the problems of high production cost and low efficiency in the prior art. In addition, the dapagliflozin upper drug layer is prepared by drug coating, which avoids the loss of raw materials in the dry granulation process and the tableting process, reduces costs while making the process simpler and greatly improving production efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] FIG1 is a dissolution curve of metformin in the dapagliflozin metformin sustained-release tablets prepared in Examples 1 to 7;
[0043] FIG2 is the dissolution curve of dapagliflozin in the dapagliflozin metformin sustained-release tablets prepared in Examples 1 to 7;
[0044] FIG3 is a graph showing the relationship between the metformin blood concentration and time for the test preparation and the reference preparation;
[0045] FIG4 is a graph showing the relationship between the blood concentration of dapagliflozin and time for the test and reference formulations;
[0046] Figure 5 is the dissolution curve of dapagliflozin metformin sustained-release tablets prepared in Comparative Example 1;
[0047] Figure 6 is the dapagliflozin dissolution curve of the dapagliflozin metformin sustained-release tablets prepared in Comparative Example 2. DETAILED DESCRIPTION
[0048] The present invention provides a dapagliflozin metformin sustained-release tablet, which comprises, from the inside to the outside, a metformin sustained-release tablet core, an isolation layer, a dapagliflozin drug layer, and a film coating layer;
[0049] The components of the metformin sustained-release tablet core include metformin hydrochloride, a binder, a hydrophilic gel skeleton sustained-release material, a glidant and a lubricant;
[0050] The components of the isolation layer include hydroxypropyl cellulose, a plasticizer and an anti-sticking agent;
[0051] The components of the dapagliflozin upper drug layer include dapagliflozin, a diluent, a plasticizer, a disintegrant and an anti-adhesive agent.
[0052] Unless otherwise specified, all raw materials used in the present invention are commercially available products.
[0053] The dapagliflozin metformin sustained-release tablets provided by the present invention include a metformin sustained-release tablet core. In the present invention, the components of the metformin sustained-release tablet core include metformin hydrochloride, a binder, a hydrophilic gel matrix sustained-release material, a glidant, and a lubricant; the binder is preferably one or more of povidone, starch slurry, ethyl cellulose, hydroxypropyl cellulose, hypromellose, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, and sucrose, and more preferably one or more of povidone, hypromellose, and hydroxypropyl cellulose; when the hydroxypropyl cellulose is used as a binder, it is preferably highly substituted hydroxypropyl cellulose (H-HPC), and the degree of substitution of the highly substituted hydroxypropyl cellulose (H-HPC) is preferably 53.4 to 77.5%.
[0054] In the present invention, the hydrophilic gel skeleton sustained-release material is one or more of hypromellose, sodium carboxymethyl cellulose, methyl cellulose, povidone, carbomer, alginate and chitosan (chitosan), more preferably hypromellose; in the present invention, the methyl substitution degree of the hypromellose is preferably 17.5-24.5%, more preferably 20.2%, and the hydroxypropyl substitution degree is preferably 22.5-27.5%, more preferably 25.4%; the apparent viscosity of the hypromellose is preferably 80,000-120,000 cp; the apparent viscosity is tested in the form of a hypromellose aqueous solution, and the concentration of the hypromellose aqueous solution is 2 wt%.
[0055] In the present invention, the lubricant is preferably one or more of magnesium stearate, sodium stearyl fumarate and talc, more preferably sodium stearyl fumarate; the glidant is preferably colloidal silicon dioxide and / or talc, more preferably colloidal silicon dioxide.
[0056] In the present invention, the components of the metformin sustained-release tablet core preferably include metformin hydrochloride, povidone, hypromellose, colloidal silicon dioxide and sodium stearyl fumarate, or include metformin hydrochloride, sodium carboxymethyl cellulose, hypromellose, colloidal silicon dioxide and sodium stearyl fumarate.
[0057] In the present invention, based on the total mass percentage of the dapagliflozin metformin sustained-release tablet as 100%, the mass percentage of each component in the metformin sustained-release tablet core is preferably: metformin hydrochloride 40-79%, more preferably 50-75%, further preferably 60-75%; binder 2-7%, more preferably 2-7%, further preferably 2-5%; hydrophilic gel skeleton sustained-release material 10-40%, more preferably 18-28%, further preferably 18-25%; glidant 0.1-2%, more preferably 0.5-2%, further preferably 0.5-1.5%; lubricant 1-10%, more preferably 1-8%, further preferably 0.5-5%.
[0058] The dapagliflozin metformin sustained-release tablets provided by the present invention include an isolation layer coated on the surface of the metformin sustained-release tablets. In the present invention, the isolation layer comprises hydroxypropyl cellulose, a plasticizer, and an anti-adherent agent; the degree of substitution of the hydroxypropyl cellulose used in the isolation layer is preferably 53.4% to 77.5%; the plasticizer is preferably one or more of polyethylene glycol, microcrystalline cellulose, polyvinyl pyrrolidone, and a water-soluble surfactant, and the water-soluble surfactant is preferably stearic acid glycerol monoester and / or sodium lauryl sulfate; in a specific embodiment of the present invention, the plasticizer is preferably polyethylene glycol; the polyethylene glycol is preferably polyethylene glycol 3350 and / or polyethylene glycol 6000; the anti-adherent agent is preferably one or more of talc, magnesium stearate, silicon dioxide, and lauryl sulfate; the lauryl sulfate is preferably sodium lauryl sulfate and / or magnesium lauryl sulfate.
[0059] In the present invention, the components of the isolation layer preferably include hydroxypropyl cellulose, polyethylene glycol and talc.
[0060] Taking the total mass percentage of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentage of each component in the isolation layer is preferably: hydroxypropyl cellulose 0.5-3%, more preferably 1-2%, and further preferably 1.25-1.75%; plasticizer 1.5-4%, more preferably 2-3.5%, and further preferably 2.5-3.2%; anti-adhesive 0.05-1.2%, more preferably 0.1-1%, and further preferably 0.3-0.6%.
[0061] The dapagliflozin metformin sustained-release tablets provided by the present invention include a dapagliflozin drug layer coated on the surface of the isolation layer. In the present invention, the components of the dapagliflozin drug layer include dapagliflozin, a diluent, a plasticizer, a disintegrant and an anti-adhesive agent; the dapagliflozin is preferably used in the form of dapagliflozin propylene glycol monohydrate. In the present invention, the mass of the dapagliflozin is based on the mass of the dapagliflozin propylene glycol monohydrate, which will not be described in detail later. In the present invention, the diluent is preferably one or more of lactose, mannitol, sorbitol, dextrin, starch, microcrystalline cellulose, inorganic calcium salt and powdered sugar, and the inorganic calcium salt is preferably one or more of calcium sulfate, calcium hydrogen phosphate and calcium carbonate; the lactose is preferably anhydrous lactose; the diluent can reduce the proportion of raw materials and improve the uniformity of the drug.
[0062] In the present invention, the disintegrant is preferably one or more of hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl starch and dry starch; when the hydroxypropyl cellulose is used as a disintegrant, it is preferably low-substituted hydroxypropyl cellulose (L-HPC), and the degree of substitution of the low-substituted hydroxypropyl methylcellulose is preferably 7-16%, more preferably 8-12%; the optional types of plasticizers and anti-sticking agents used in the dapagliflozin upper drug layer are preferably consistent with the above-mentioned scheme, and will not be repeated here; the addition of an anti-sticking agent to the dapagliflozin upper drug layer of the present invention can prevent adhesion during the coating process.
[0063] In the present invention, the ingredients of the dapagliflozin upper drug layer preferably include dapagliflozin, polyethylene glycol, talc, lactose and hydroxypropyl cellulose, or include dapagliflozin, polyethylene glycol, talc, mannitol and hydroxypropyl cellulose; the hydroxypropyl cellulose is preferably low-substituted hydroxypropyl cellulose, and the degree of substitution of the low-substituted hydroxypropyl methylcellulose is consistent with the above-mentioned scheme, which will not be repeated here.
[0064] In the present invention, based on the total mass percentage of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentage of each component in the dapagliflozin upper drug layer is preferably: dapagliflozin 0.2-2%, more preferably 0.5-1.5%, further preferably 0.5-1%; diluent 2-15%, more preferably 5-10%; plasticizer 0.5-4%, preferably 0.6-3.5%, further preferably 0.8-3.2%; disintegrant 1.5-5%, preferably 1.7-4.5%, further preferably 2-4%; anti-adhesive 0.05-3%, more preferably 0.05-2%, further preferably 0.05-1.5%.
[0065] The dapagliflozin metformin sustained-release tablets provided herein include a film coating layer coated on the surface of the dapagliflozin upper drug layer. In the present invention, the film coating layer is preferably composed of Opadry coating powder. Based on the total mass percentage of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentage of the Opadry coating powder is preferably 1 to 4%, more preferably 1.2 to 3.5%.
[0066] In the present invention, the content of metformin hydrochloride in each dapagliflozin metformin sustained-release tablet is preferably 400-1200 mg, more preferably 800-1000 mg, the content of dapagliflozin is preferably 1-12 mg, more preferably 5-12 mg, and the weight of each dapagliflozin metformin sustained-release tablet is preferably 850-1800 mg.
[0067] The present invention also provides a method for preparing the dapagliflozin metformin sustained-release tablets described in the above scheme, comprising the following steps:
[0068] Wetting metformin hydrochloride and a binder and then performing wet granulation, mixing the obtained drug granules with a hydrophilic gel matrix sustained-release material, a lubricant, and a glidant, and tableting to obtain metformin sustained-release tablet cores;
[0069] mixing the components of the isolation layer with water to obtain an isolation layer coating paste; and coating the metformin sustained-release tablet core with the isolation layer coating paste to obtain metformin sustained-release isolation-coated tablets;
[0070] Mixing the components of the dapagliflozin upper drug layer with water to obtain an upper drug solution; applying the upper drug solution to the metformin sustained-release isolation-coated tablets to obtain dapagliflozin metformin sustained-release tablets;
[0071] The dapagliflozin metformin sustained-release tablets are film-coated with a film coating slurry to obtain the dapagliflozin metformin sustained-release tablets.
[0072] The present invention wets metformin hydrochloride and a binder and then performs wet granulation. The resulting drug particles are mixed with a hydrophilic gel skeleton sustained-release material, a lubricant, and a glidant for tableting to obtain metformin sustained-release tablet cores. In the present invention, the metformin hydrochloride is preferably sieved before use, and the mesh size of the sieve is preferably 20 mesh. The present invention removes lumps in the raw materials by sieving; the wetting agent is preferably purified water; the amount of the wetting agent is preferably 2-4% of the mass of the metformin hydrochloride; the present invention has no special requirements for the specific operating conditions of the wet granulation, and those familiar to those skilled in the art can be used; the drug particles obtained by the wet granulation are preferably dried and then mixed with the hydrophilic gel skeleton sustained-release material, etc.; the tableting pressure is preferably 12-20N, and the tableting is preferably performed using an elliptical special-shaped punch.
[0073] After obtaining the metformin sustained-release tablet core, the present invention mixes the components of the isolation layer with water to obtain an isolation layer coating slurry; the isolation layer coating slurry is used to perform isolation coating on the metformin sustained-release tablet core to obtain metformin sustained-release isolation-coated tablets. In the present invention, the solid content of the isolation layer coating slurry is preferably 10-20 wt%, more preferably 13-17 wt%; the isolation layer coating is preferably carried out in a coating pan; the operating parameters of the isolation layer coating preferably include: a spray rate of the isolation layer coating slurry of 50-100 g / min, preferably 60-80 g / min, a rotation speed of the coating pan of 3-8 r / min, preferably 4-6 r / min, and a temperature of the material in the coating pan of 38-45°C, preferably 40-42°C; the isolation layer coating preferably has a weight gain of 4-10%, more preferably 5-8%.
[0074] After obtaining metformin sustained-release isolation-coated tablets, the present invention mixes the components of the dapagliflozin upper drug layer with water to obtain an upper drug solution; the upper drug solution is used to apply the metformin sustained-release isolation-coated tablets to obtain dapagliflozin metformin sustained-release tablets. The present invention does not specifically limit the specific method of mixing the upper drug layer components with water, and methods well known to those skilled in the art can be used, such as shearing. Preferably, the components of the dapagliflozin upper drug layer and water are sheared at a speed of 1000 rpm for 5 minutes; the solid content of the upper drug solution is preferably 15 to 35 wt%, more preferably 20 to 30 wt%; the particle size of the dapagliflozin is preferably less than 10 μm.
[0075] In the present invention, the drug application is preferably carried out in a coating pot; the operating parameters of the drug application preferably include: a spray rate of the drug solution of 50 to 230 g / min, preferably 80 to 200 g / min, a rotation speed of the coating pot of 3 to 12 r / min, preferably 5 to 10 r / min, and a temperature of the material in the coating pot of 38 to 45°C, preferably 40 to 42°C; the drug preferably gains a weight of 210 to 260 mg, more preferably 220 to 250 mg.
[0076] After obtaining the dapagliflozin metformin sustained-release tablets, the present invention uses a film coating slurry to film-coat the dapagliflozin metformin sustained-release tablets to obtain the dapagliflozin metformin sustained-release tablets. In the present invention, the film coating slurry is preferably prepared from Opadry coating powder and water, and specifically a commercially available film coating premix (gastric soluble) can be used; the solid content of the film coating slurry is preferably 8 to 12 wt%.
[0077] In the present invention, the film layer coating is preferably carried out in a coating pan; the operating parameters of the film layer coating preferably include: the spray rate of the film layer coating slurry is 50 to 100 g / min, preferably 60 to 80 mg / min, the rotation speed of the coating pan is 3 to 8 r / min, preferably 4 to 7 r / min, and the temperature of the material in the coating pan is 38 to 45°C, preferably 40 to 42°C; the film layer coating preferably gains weight by 0.5 to 4%, more preferably 1 to 3%.
[0078] After the film layer coating is completed, the present invention preferably further comprises packaging the dapagliflozin metformin sustained-release tablets in high-density polyethylene bottles.
[0079] The present invention also provides the use of the dapagliflozin metformin sustained-release tablets described in the above scheme or the dapagliflozin metformin sustained-release tablets prepared by the preparation method described in the above scheme in the preparation of a drug for treating type 2 diabetes; the present invention has no special requirements for the said application, and methods well known to those skilled in the art can be used.
[0080] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.
[0081] In the following examples, the methyl substitution degree of the hypromellose used in the metformin sustained-release tablet core is 20.2%, and the hydroxypropyl substitution degree is 25.4%; the substitution degree of the hydroxypropyl cellulose used in the isolation layer is 60%, and the substitution degree of the hydroxypropyl cellulose (disintegrant) used in the dapagliflozin upper drug layer is 10%.
[0082] Example 1
[0083] The composition of dapagliflozin metformin sustained-release tablets is shown in Table 1:
[0084] Table 1 Prescription composition of dapagliflozin metformin sustained-release tablets
[0085] The preparation method of dapagliflozin metformin sustained-release tablets is as follows:
[0086] Metformin hydrochloride and povidone were moistened with purified water and then wet granulated. The resulting drug granules were dried. Hydroxypropyl methylcellulose, colloidal silicon dioxide, and sodium stearyl fumarate were added to the dried drug granules and mixed. The mixture was then compressed using an oval die at a pressure of 15 kN to obtain metformin sustained-release tablet cores (tablet weight 1.405 g).
[0087] Seal coating: The components of the seal layer were mixed with water to form a seal coating slurry with a solid content of 10%. The metformin sustained-release tablet cores were coated in a coating pan to obtain metformin sustained-release seal-coated tablets. The operating parameters were: a spray rate of the seal coating slurry of 50 to 100 g / min, a rotation speed of the coating pan of 3 rpm, and a temperature of the material in the coating pan of 40°C (tablet weight 1.490 g).
[0088] Drug application: Dapagliflozin propylene glycol monohydrate, low-substituted hydroxypropyl cellulose, anhydrous lactose, polyethylene glycol 3350, and talc are dissolved in water and high sheared at a speed of 1000 r / min for 5 minutes to obtain a drug solution with a solid content of 20%; metformin sustained-release isolation coated tablets are coated in a coating pan to obtain dapagliflozin metformin sustained-release tablets. The operating parameters are: spray rate of the drug solution 60-120 g / min, coating pan speed 3-10 r / min, and material temperature 40°C (tablet weight 1.644 g).
[0089] Film coating: Dapagliflozin metformin sustained-release tablets were coated with a film coating slurry to obtain dapagliflozin metformin sustained-release tablets. The operating parameters were: film coating slurry spray rate of 60 g / min, coating pan speed of 3 r / min, and material temperature of 40°C (tablet weight of 1.670 g / tablet).
[0090] The subsequent Examples 2 to 7 and Comparative Examples 2 to 3 were prepared according to this process, and the tablet weight error in each step was controlled within ±3%.
[0091] Example 2
[0092] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1, with only the prescription composition being changed. The prescription composition of the dapagliflozin metformin sustained-release tablets in Example 2 is shown in Table 2:
[0093] Table 2 Prescription composition of dapagliflozin metformin sustained-release tablets
[0094] Example 3
[0095] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1, with only the prescription composition being changed. The prescription composition of the dapagliflozin metformin sustained-release tablets in Example 3 is shown in Table 3:
[0096] Table 3 Prescription composition of dapagliflozin metformin sustained-release tablets
[0097] Example 4
[0098] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1, with only the prescription composition being changed. The prescription composition of the dapagliflozin metformin sustained-release tablets in Example 4 is shown in Table 4:
[0099] Table 4 Prescription composition of dapagliflozin metformin sustained-release tablets
[0100] Example 5
[0101] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1, with only the prescription composition being changed. The prescription composition of the dapagliflozin metformin sustained-release tablets in Example 5 is shown in Table 5:
[0102] Table 5 Prescription composition of dapagliflozin metformin sustained-release tablets
[0103] Example 6
[0104] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1, with only the prescription composition being changed. The prescription composition of the dapagliflozin metformin sustained-release tablets in Example 6 is shown in Table 6:
[0105] Table 6 Prescription composition of dapagliflozin metformin sustained-release tablets
[0106] Example 7
[0107] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1, with only the prescription composition being changed. The prescription composition of the dapagliflozin metformin sustained-release tablets in Example 7 is shown in Table 7:
[0108] Table 7 Prescription composition of dapagliflozin metformin sustained-release tablets
[0109] Test Experiment
[0110] (1) Dissolution performance test of metformin and dapagliflozin in dapagliflozin metformin sustained-release tablets:
[0111] The dissolution curves of the dapagliflozin metformin sustained-release tablets prepared in Test Examples 1 to 7 were tested. The dissolution medium was: pH 6.8 phosphate buffer, water, pH 1.0 hydrochloric acid solution, and pH 4.5 acetate buffer. The dissolution conditions were: the dissolution medium was 1000 mL, 12 tablets of the test sample were placed in a sinker, the speed was 75 rpm, and the operation was carried out according to the law. Sampling tests were performed after 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, and 720 min. The dissolution results are shown in Figures 1 to 2. The reference preparation used was dapagliflozin metformin sustained-release tablets ( XR, strength: 10 mg / 1000 mg; manufactured by AstraZeneca Pharmaceuticals LP).
[0112] Figure 1 is the dissolution curve of metformin in the dapagliflozin metformin sustained-release tablets prepared in Examples 1 to 7; Figure 2 is the dissolution curve of dapagliflozin metformin sustained-release tablets prepared in Examples 1 to 7; It can be seen from Figures 1 to 2 that the in vitro dissolution curves of dapagliflozin and metformin in the dapagliflozin metformin sustained-release tablets prepared by the present invention are consistent with those of the reference preparation.
[0113] (2) Uniformity test
[0114] The content uniformity of the dapagliflozin metformin sustained-release tablets prepared in Examples 1 to 7 was tested. The test method was based on the general rules of Part IV of the Chinese Pharmacopoeia. The test results are shown in Table 8:
[0115] Table 8 Content uniformity test results
[0116] (3) In vivo testing:
[0117] The study compared the effects of a single oral administration of the test preparation dapagliflozin metformin sustained-release tablets (specification: 10 mg / 1000 mg, prepared in Example 1) and the reference preparation dapagliflozin metformin sustained-release tablets ( The pharmacokinetic characteristics of the test and reference formulations (10 mg / 1000 mg, manufactured by AstraZeneca Pharmaceuticals LP) were evaluated in healthy volunteers after oral administration in the fasting and fed states. The relationship between the metformin plasma concentration and time of the test and reference formulations is shown in Figure 3, and the relationship between the metformin plasma concentration and time of dapagliflozin is shown in Figure 4.
[0118] 3 and 4 , it can be seen that the pharmacokinetic characteristics of the dapagliflozin metformin sustained-release tablets prepared by the present invention are similar to those of the reference preparation, indicating that the in vivo pharmacodynamics of the dapagliflozin metformin sustained-release tablets prepared by the present invention are consistent with those of the reference preparation.
[0119] Comparative Example 1
[0120] Omit the isolation layer, and the formula composition is shown in Table 9:
[0121] Table 9 Prescription composition of dapagliflozin metformin sustained-release tablets
[0122] The preparation method is as follows:
[0123] Metformin hydrochloride and povidone were moistened with purified water and then wet granulated. The resulting drug granules were dried. Hydroxypropyl methylcellulose, colloidal silicon dioxide, and sodium stearyl fumarate were added to the dried drug granules and mixed. The mixture was then compressed using an oval die at a pressure of 15 kN to obtain metformin sustained-release tablet cores (tablet weight approximately 1.405 g).
[0124] Drug application: Dissolve dapagliflozin propylene glycol monohydrate, low-substituted hydroxypropyl cellulose, anhydrous lactose, polyethylene glycol 3350, and talc in water and high shear at a speed of 1000 r / min for 5 minutes to obtain a drug solution with a concentration of 10%; coat metformin sustained-release isolation coated tablets in a coating pan to obtain dapagliflozin metformin sustained-release tablets. The operating parameters are: spray rate of the drug solution 60-120 g / min, coating pan speed 3-10 r / min, and material temperature 40°C (tablet weight 1.560 g).
[0125] Film coating: Dapagliflozin metformin sustained-release tablets were coated with a film coating slurry to obtain dapagliflozin metformin sustained-release tablets. The operating parameters were: film coating slurry spray rate of 60 g / min, coating pan speed of 3 r / min, and material temperature of 40°C (tablet weight of 1.584 g / tablet).
[0126] The dissolution profile of the dapagliflozin metformin sustained-release tablets prepared in Comparative Example 1 was tested according to the dissolution test method described above and compared with that in Example 1. The results are shown in Figure 5. As can be seen from Figure 5, after omitting the isolation layer, the isolation sustained-release material in the metformin sustained-release tablet core acts as an adsorbent to the dapagliflozin raw material, resulting in a delayed dissolution of dapagliflozin.
[0127] Comparative Example 2
[0128] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1. The only difference from Example 1 was that the isolation layer was replaced with Opadry coating powder. The specific formulation composition is shown in Table 10:
[0129] Table 10 Prescription composition of dapagliflozin metformin sustained-release tablets
[0130] The dissolution profile of dapagliflozin and metformin sustained-release tablets prepared in Comparative Example 1 was tested according to the above-described dissolution test method and compared with that in Example 1. The results are shown in Figure 6. As can be seen from Figure 6, the use of ordinary Opadry coating powder as a barrier layer fails to isolate the sustained-release material from adsorption of the dapagliflozin raw material, and the problem of delayed dissolution of dapagliflozin still exists.
[0131] Comparative Example 3
[0132] Dapagliflozin metformin sustained-release tablets were prepared according to the method of Example 1. The only difference from Example 1 was that the diluent and disintegrant in the dapagliflozin upper drug layer were omitted. The specific formulation composition is shown in Table 11.
[0133] Table 11 Prescription composition of dapagliflozin metformin sustained-release tablets
[0134] The content uniformity of the dapagliflozin metformin sustained-release tablets prepared in Comparative Example 3 was tested, and the results are shown in Table 12.
[0135] Table 12 Comparative Example 3 Content Uniformity Test Results
[0136] According to the results in Table 12, it can be seen that after omitting the diluent and disintegrant in the upper drug layer, the uniformity of the dapagliflozin content deteriorates.
[0137] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A dapagliflozin metformin sustained-release tablet, characterized in that: From the inside to the outside, it includes a metformin sustained-release tablet core, a separation layer, a dapagliflozin drug layer and a film coating layer; The components of the metformin sustained-release tablet core include metformin hydrochloride, a binder, a hydrophilic gel skeleton sustained-release material, a glidant and a lubricant; The components of the isolation layer include hydroxypropyl cellulose, a plasticizer and an anti-adhesive agent; The components of the dapagliflozin upper drug layer include dapagliflozin, a diluent, a plasticizer, a disintegrant and an anti-adhesive agent.
2. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: Taking the total mass of the dapagliflozin metformin sustained-release tablet as 100%, the mass percentage of each component in the metformin sustained-release tablet core is: 40-79% of metformin hydrochloride, 2-7% of binder, 10-40% of hydrophilic gel skeleton sustained-release material, 0.1-2% of glidant, and 1-10% of lubricant.
3. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: Taking the total mass of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentages of the components in the isolation layer are: 0.5-3% hydroxypropyl cellulose, 1.5-4% plasticizer, and 0.05-1.2% anti-adhesive agent.
4. The dapagliflozin metformin sustained-release tablets according to claim 1 or 3, characterized in that: The degree of substitution of the hydroxypropyl cellulose used in the isolation layer is 53.4% to 77.5%.
5. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: Taking the total mass of the dapagliflozin metformin sustained-release tablet as 100%, the mass percentage of each component in the dapagliflozin upper drug layer is: dapagliflozin 0.2-2%, diluent 2-15%, plasticizer 0.5-4%, disintegrant 1.5-5%, and anti-adhesive agent 0.05-3%.
6. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The film coating layer is composed of Opadry coating powder. Based on the total mass of the dapagliflozin metformin sustained-release tablets as 100%, the mass percentage of the Opadry coating powder is 1-4%.
7. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The binder is one or more of povidone, starch slurry, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol and sucrose; The hydrophilic gel skeleton sustained-release material is one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methyl cellulose, povidone, carbomer, alginate and chitosan; The lubricant is one or more of magnesium stearate, sodium stearyl fumarate and talc; The glidant is colloidal silicon dioxide and / or talc.
8. The dapagliflozin metformin sustained-release tablet according to claim 7, characterized in that: When used as a binder, the degree of substitution of the hydroxypropyl cellulose is 53.4-77.5%.
9. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The plasticizers used in the isolation layer and the dapagliflozin drug layer are independently selected from one or more of polyethylene glycol, microcrystalline cellulose, polyvinyl pyrrolidone and a water-soluble surfactant.
10. The dapagliflozin metformin sustained-release tablet according to claim 9, characterized in that: The polyethylene glycol is polyethylene glycol 3350 and / or polyethylene glycol 6000; the water-soluble surfactant is stearic acid glyceryl monoester and / or sodium lauryl sulfate.
11. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The anti-adhesive agents used in the isolation layer and the dapagliflozin drug layer are independently one or more of talc, magnesium stearate, silicon dioxide and lauryl sulfate.
12. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The diluent is one or more of lactose, mannitol, sorbitol, dextrin, starch, microcrystalline cellulose, inorganic calcium salt and powdered sugar.
13. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The disintegrant is one or more of hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl starch and dry starch.
14. The dapagliflozin metformin sustained-release tablet according to claim 13, characterized in that: When used as a disintegrant, the degree of substitution of the hydroxypropyl cellulose is 7 to 16%.
15. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The components of the metformin sustained-release tablet core include metformin hydrochloride, povidone, hypromellose, colloidal silicon dioxide and sodium stearyl fumarate, or include metformin hydrochloride, sodium carboxymethyl cellulose, hypromellose, colloidal silicon dioxide and sodium stearyl fumarate; The components of the isolation layer include hydroxypropyl cellulose, polyethylene glycol and talc; The ingredients of the dapagliflozin upper drug layer include dapagliflozin, polyethylene glycol, talc, lactose and hydroxypropyl cellulose, or include dapagliflozin, polyethylene glycol, talc, mannitol and hydroxypropyl cellulose.
16. The dapagliflozin metformin sustained-release tablet according to claim 1, characterized in that: The content of metformin hydrochloride in each dapagliflozin metformin sustained-release tablet is 400-1200 mg, and the content of dapagliflozin is 1-12 mg; the weight of each dapagliflozin metformin sustained-release tablet is 850-1800 mg.
17. The method for preparing the dapagliflozin metformin sustained-release tablets according to any one of claims 1 to 16, characterized in that: The following steps are involved: Wetting metformin hydrochloride and a binder and then performing wet granulation, mixing the obtained drug particles with a hydrophilic gel skeleton sustained-release material, a lubricant and a glidant and performing tablet compression to obtain a metformin sustained-release tablet core; Mixing the components of the isolation layer with water to obtain an isolation layer coating paste; applying an isolation layer coating to the metformin sustained-release tablet core using the isolation layer coating paste to obtain a metformin sustained-release isolation-coated tablet; Mixing the components of the dapagliflozin drug layer with water to obtain a drug solution; applying the drug solution to the metformin sustained-release isolation coated tablets to obtain dapagliflozin metformin sustained-release tablets; The dapagliflozin metformin sustained-release tablets are film-coated with a film coating slurry to obtain the dapagliflozin metformin sustained-release tablets.
18. The preparation method according to claim 17, characterized in that: The wetting agent is purified water; the dosage of the wetting agent is 2-4% of the mass of the metformin hydrochloride; and the obtained drug particles are dried after wet granulation.
19. The preparation method according to claim 17, characterized in that: The isolation layer coating, drug application and film layer coating are all carried out in a coating pan; the operating parameters of the isolation layer coating include: the spray rate of the isolation layer coating slurry is 50-100 g / min, the rotation speed of the coating pan is 3-8 r / min, and the temperature of the material in the coating pan is 38-45° C.; The operation parameters of the drug application include: the spray rate of the drug solution is 50-230 g / min, the rotation speed of the coating pan is 3-12 r / min, and the temperature of the material in the coating pan is 38-45°C; The operating parameters of the film layer coating include: the spraying speed of the film layer coating slurry is 50-100 g / min, the rotation speed of the coating pan is 3-8 r / min, and the temperature of the material in the coating pan is 38-45°C.
20. Use of the dapagliflozin metformin sustained-release tablets according to any one of claims 1 to 16 or the dapagliflozin metformin sustained-release tablets prepared by the preparation method according to any one of claims 17 to 19 in the preparation of a medicament for treating type 2 diabetes.
21. A method for treating type 2 diabetes, characterized in that: The treatment is carried out by taking the dapagliflozin metformin sustained-release tablets according to any one of claims 1 to 16 or the dapagliflozin metformin sustained-release tablets prepared by the preparation method according to any one of claims 17 to 19.
Citation Information
Patent Citations
Composite pioglitazone melbine sustained release tablet and preparation method thereof
CN106137999A
Compound dapagliflozin metformin sustained release tablet and preparation method thereof
CN106924208A
Saxagliptin and metformin hydrochloride sustained-release tablet
CN112494485A
Dapagliflozin and metformin sustained release preparation and preparation method thereof
CN113398097A
Dapagliflozin and metformin sustained release tablet as well as preparation method and application thereof
CN116473934A
